ANAB - צמיחת מכירות משנה לשנה (TTM) AnaptysBio, Inc.

Volatility, evident in the trend of the rolling annual sales growth, is linked to the asset-light model and the outsourcing of antibody production. Stability is provided by strong patents, which allow the company to dictate licensing terms, and intensive clinical trials of new drugs. Consequently, 13.30 becomes the new value of the indicator, capturing the current business development vector of AnaptysBio, Inc. (ANAB) on the chart.
AnaptysBio, Inc. - פילוחים אנליטיים ומדדי מפתח (ANAB)

AnaptysBio, Inc. (ANAB) development of innovative antibodies for the therapy of asthma and dermatitis directly impacts commercial revenue dynamics, as reflected by this indicator. By analyzing the trailing twelve-month (TTM) sales growth rate, an investor assesses daily revenue changes over the year, enabling the timely identification of demand phases and the avoidance of purchasing overvalued assets at the peak of the curve.